Core Viewpoint - Kingsray Biotechnology (01548.HK) announced that its associate company, Legend Biotech, has submitted a 6-K form to the U.S. Securities and Exchange Commission, reporting trade sales net revenue of approximately $555 million for CARVYKTI® for the quarter ending December 31, 2025 [1]. Group 1 - The announcement was made on January 21, 2026, after the Hong Kong trading session [1]. - The trade sales net revenue figure is based on information provided by Janssen Biotech, Inc., and has not been independently verified by either Legend or Kingsray [1].

Core Viewpoint - Kingsray Biotechnology (01548) announced that CARVYKTI® is expected to generate approximately $555 million in net trade sales for the quarter ending December 31, 2025, based on the collaboration and licensing agreement established with Janssen Biotech, Inc. on December 21, 2017 [1] Group 1 - Kingsray Biotechnology has a collaboration and licensing agreement with Janssen Biotech, Inc. [1] - The projected net trade sales for CARVYKTI® are significant, amounting to approximately $555 million [1]

Genscript Biotech Corporation （於開曼群島註冊成立的有限公司） （股份代號：1548） 自願性公告 傳奇宣佈截至2025年12月31日止季度 CARVYKTI®的初步銷售額 本自願性公告由金斯瑞生物科技股份有限公司（「本公司」）作出。 茲提述本公司日期爲2025年4月15日、2025年7月16日及2025年10月14日的公告，内容 分別有關截至2025年3月31日止季度、截至2025年6月30日止季度及截至2025年9月30日 止季度CARVYKTI®的初步銷售額。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 1 或有效性資料或資料分析，或一般的政府監管；因傳奇的第三方合作夥伴採取的行動 或未有採取行動而導致的意外延誤；因對傳奇的專利或其他專有知識產權保護提出質 疑而產生的不確定性，包括美國訴訟程序中涉及的不確定性；一般競爭；政府、行業 和公眾定價和其他政治壓力；以及於2025年3月11日向美國證券交易委員會提交的傳奇 ...

Core Insights - Legend Biotech has been awarded the Foreign Investor of the Year at the 2025 Flanders International Business Awards, recognizing its significant contributions to the region's biotech sector [1][2] - The company has made a €165 million joint investment with Johnson & Johnson to expand its manufacturing facility in Ghent, enhancing its position as a major CAR-T manufacturing center in Europe [3][4] Company Growth and Operations - Since starting operations in Ghent in 2022, Legend Biotech's workforce has grown from 2 to over 1,000 employees, representing 66 nationalities, with plans for further hiring in the coming years [4] - The Ghent facility, along with the nearby Obelisc site, serves as the European hub for clinical and commercial supply of cell therapies across the EMEA region [3] Strategic Partnerships and Ecosystem - Legend Biotech's growth is closely linked to the strength of the Flemish biotech ecosystem, supported by partnerships with Flanders Investment & Trade (FIT) and collaborations with research institutions like VIB and Ghent University [5] - The company aims to leverage its leadership in CAR-T cell therapy to maximize patient access and drive future innovations in cell therapy modalities [6]

Core Viewpoint - Kingsray Biotechnology (01548) announced that its affiliate Legend Biotech Corporation will present the latest data related to CARVYKTI® and other pipelines at the 67th American Society of Hematology Annual Meeting from December 6 to 9, 2025, in San Diego [1] Group 1 - Kingsray Biotechnology's affiliate, Legend Biotech Corporation, submitted a 6-K form to the U.S. Securities and Exchange Commission on November 3, 2025 [1] - The presentation at the American Society of Hematology Annual Meeting will showcase advancements related to CARVYKTI® [1]

Core Viewpoint - Kingsray Biotechnology (01548.HK) announced that its affiliate, Legend Biotech Corporation, submitted a 6-K form to the U.S. Securities and Exchange Commission on November 3, 2025, and will present the latest data related to CARVYKTI® and other pipelines at the 67th American Society of Hematology Annual Meeting from December 6 to 9, 2025, in San Diego [1]. Group 1 - Kingsray Biotechnology's affiliate, Legend Biotech, is listed on the NASDAQ Global Select Market [1]. - The 67th American Society of Hematology Annual Meeting will take place in San Diego [1]. - The presentation will include the latest data on CARVYKTI® and other related pipelines [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任 何責任。 Genscript Biotech Corporation （於開曼群島註冊成立的有限公司） （股份代號：1548） 關於前瞻性陳述的注意事項 本公告中關於未來預期、計劃和前景的陳述，以及關於非歷史事實事項的任何其他陳述，均構 成1995年《私人證券訴訟改革法案》所指的「前瞻性陳述」。這些陳述包括但不限於：與傳奇 戰略和目標有關的表述，以及傳奇候選產品的潛在優勢。「預期」、「相信」、「繼續」、 「可能」、「估計」、「期望」、「打算」、「可以」、「計劃」、「潛在」、「預測」、 「預計」、「應該」、「目標」、「將」、「會」和類似表達旨在識別前瞻性陳述，但並非所 有前瞻性陳述都包含這些識別詞。儘管並非所有前瞻性表述都包含這些識別詞，但類似表述旨 在識別前瞻性表述。由於各種重要因素的影響，實際結果可能與這些前瞻性陳述所顯示的結果 存在實質性差異。傳奇的預期可能會受到以下因素的影響：新藥開發過程中的不確定性；意外 ...

Core Viewpoint - Kingsoft Biotech (1548.HK) has seen a significant stock price increase of 4.71% to HKD 16.67, with a year-to-date gain of nearly 70%, outperforming the market index which has risen approximately 30% during the same period [1] Group 1: Company Performance - Kingsoft Biotech's stock price has increased by 4.71% to HKD 16.67 during intraday trading [1] - The company has achieved a year-to-date stock price increase of nearly 70% [1] - The performance of Kingsoft Biotech has outpaced the Hang Seng Index, which has risen about 30% in the same timeframe [1] Group 2: Business Developments - Kingsoft Biotech announced that its affiliate, Legend Biotech Corporation, submitted a 6-K form to the U.S. Securities and Exchange Commission on October 14, 2025 [1] - The report indicated that CARVYKTI® generated trade sales net revenue of approximately USD 524 million for the quarter ending September 30, 2025, under a collaboration and licensing agreement with Janssen Biotech, Inc. established on December 21, 2017 [1]

Group 1 - Kingsray Biotechnology (01548) saw a stock increase of over 3%, currently trading at 16.27 HKD with a transaction volume of 32.066 million HKD [1] - On October 14, Kingsray Biotechnology announced that, according to the collaboration and licensing agreement established with Janssen Biotech, Inc. on December 21, 2017, CARVYKTI® is expected to generate net trade sales of approximately 524 million USD for the quarter ending September 30, 2025 [1]

Core Viewpoint - Kingsray Biotechnology (01548) has seen a stock price increase of over 3%, currently trading at 16.27 HKD with a transaction volume of 32.066 million HKD, following the announcement of projected trade sales from its collaboration with Janssen Biotech, Inc. [1] Group 1 - Kingsray Biotechnology announced that CARVYKTI is expected to generate trade sales net revenue of approximately 524 million USD for the quarter ending September 30, 2025, as per the collaboration and licensing agreement established with Janssen on December 21, 2017 [1]